Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI:"SCI-COG" Study

CompletedNot a drug-phase studyEarly (CIS/RIS)NCT01865357

What it found

Paper found, not read

A paper reports the results; we have not read it yet. See Papers below.

What was tested

Treatment tested

  • Brain MRI - Clinical and cognitive evaluation
  • Eye movement

What it measured

Main measures

  • Correlation between fractional anisotropy (FA) value and cognitive z scores or cognitive impairment indexes for each domains

    visit 2 - 1 year after inclusion

    MRI lesionsThinking and memory

Other measures (6)

  • Comparison of skeleton of FA between CIS patients and healthy subjects

    V2 - 1 year after the inclusion

  • Comparison of cognitive scores at each test between CIS patients and controls

    D0 and V2 - 1 year after the inclusion

    Thinking and memory
  • Proportion of patients with cognitive impairment (≥ 3 tests impaired) and correlations with anxiety, depressive syndrome and fatigue

    D0 and V2 - 1 year after the inclusion

    Thinking and memoryFatigueMood and sleep
  • Comparison of statistical maps of FA

    D0 and V2 - 1 year after the inclusion

    Thinking and memory
  • Correlations between cognitive scores and mean cortical thickness and deep grey nuclei volumes in CIS patients

    D0 and V2 - 1 year after the inclusion

    Thinking and memory
  • Comparison of cognitive scores at each test and eye movements scores

    D0 and V2 - 1 year after the inclusion

    Thinking and memoryNerve conduction tests

Who could take part

Early (CIS/RIS) · 18 and over

Show the full criteria

Inclusion criteria

* Patients: * Men and Women * ≥16 years * Fluent French speaker * Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation * Between 60 and 180 days from the onset * At least two clinically silent lesions on their T2-weighted brain or spinal MRI scan with a size of at least 3 mm, at least one of which being cerebral, ovoid, or periventricular * Having a medical insurance * Free and informed consent signed * Controls: * Men and Women * ≥18 years * Fluent French speaker * Having a medical insurance * Free and informed consent signed

Exclusion criteria

* Patients: * Prior documented neurological episode suggestive of MS. * Other ongoing neurological diseases. * Known chronic systemic diseases as judged by the investigator (for instance: lupus, Gougerot-Sjögren, sarcoidosis, sclerodermia, Crohn disease,…). * Other causes (trauma, tumor, radiotherapy, infections, vascular diseases, neuromyelitis optica). * Current dependence on alcohol or drugs. * Dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 15 days * MRI contra-indications. * Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily. * Controls: * Known chronic psychiatric or neurologic diseases which could interfere with neuropsychological testing, not taking into account stable and mild depressive syndrome * Known chronic systemic diseases as judged by the investigator (for instance: lupus, Gougerot-Sjögren, sarcoidosis, scleroderma, Crohn disease…). * MS familial history * Current dependence on alcohol or drugs * Known cognitive impairment * Prior neuropsychological testing with the same tests less than one year * Dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 2 months * Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily. * MRI contra-indications * Steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Clinically isolated demyelinating syndromes (CIS) can evolve into multiple sclerosis (MS). Cognitive deficiencies could occur at this early stage and concern mainly information processing speed (IPS) and their mechanisms are not fully understood. Diffusion Tensor Imaging (DTI) can help in the understanding of these mechanisms.

Papers

Loading reviews and guidelines…

History

    1. Started

      Aug 2012

    2. Main results due

      Dec 2016

    3. Finished

      Dec 2016

    Assembled by software from public sources.